Abstract: An authentication system handles authentication requests to apply introspection and policy enforcement. A policy server obtains a client security policy and an authenticator security policy. The policy server obtains an encrypted credential request with client metadata from a client and determines whether the client metadata satisfies the client security policy. The policy server provides the encrypted credential request to an authenticator device and obtains an encrypted credential response with authenticator metadata in response. The policy server determines whether the authenticator metadata satisfies the authenticator security policy. The policy server processes the encrypted credential response, without decrypting the encrypted credential request or the encrypted credential response, based on a determination of whether the client metadata satisfies the client security policy and the authenticator metadata satisfies the authenticator security policy.

Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

Abstract: System and methods for marking a work area boundary of an autonomous vehicle are disclosed. A system may receive an indication that boundary marking for a work area is to be activated, and may transmit an activation signal to a marking actuator based on receiving the indication that boundary marking for the work area is to be activated. The activation signal may cause the marking actuator to begin marking the boundary as a vehicle, that includes the system, traverses the boundary. The system may store information that identifies a plurality of marked locations along the boundary. The system may determine that boundary marking for the work area is to be deactivated, and may transmit a deactivation signal to the marking actuator based on determining that boundary marking for the work area is to be deactivated. The deactivation signal may cause the marking actuator to stop marking the boundary.

Abstract: In one representative embodiment, a vehicle has a frame, a material hopper mounted on the frame, a swing arm assembly coupled to the frame, and a conveyor mounted on the swing arm assembly. The swing arm assembly can have a support bracket configured to pivot relative to the hopper about a vertical pivot axis, the support bracket also configured to pivot relative to the hopper about a horizontal pivot axis, wherein the support bracket is configured to support the conveyor for pivoting movement of the conveyor relative to the hopper about the vertical pivot axis and about the horizontal pivot axis to move the conveyor from a first, stowed position extending alongside one of the sides of the hopper to a second, use position extending rearwardly away from the rear end of the hopper.

Abstract: Embodiments are disclosed herein that relate to tuning gesture recognition characteristics for a device configured to receive gesture-based user inputs. For example, one disclosed embodiment provides a head-mounted display device including a plurality of sensors, a display configured to present a user interface, a logic machine, and a storage machine that holds instructions executable by the logic machine to detect a gesture based upon information received from a first sensor of the plurality of sensors, perform an action in response to detecting the gesture, and determine whether the gesture matches an intended gesture input. The instructions are further executable to update a gesture parameter that defines the intended gesture input if it is determined that the gesture detected does not match the intended gesture input.

Abstract: Bifunctional molecules having first and second alpha-synuclein binding agents coupled by a linker are disclosed. The bifunctional molecules have potential utility in the diagnosis, treatment and/or prophylaxis of disorders in which alpha-synuclein is implicated, including Parkinson's disease. Methods of making and using the bifunctional molecules are disclosed.

Abstract: A computer-implemented method for retrieving information from information services and providing it to a public application programming interface (API) includes receiving a first request data message using a core discovery agent, the request data message including at least one requested datum, for which a value is sought, and at least one known datum, for which a value is known; calling a resource locator to request a location of an information service that provides a value for the requested datum; calling a resource façade to contact the information service; transmitting a first information service message including the requested datum and known datum from the resource façade to the information service; receiving a second information service message from the information service including a value for the requested datum; and transmitting a resolved data message including the requested datum and its value from the core discovery agent to the public API.

Abstract: The disclosure relates to compositions comprising a HBV RNAi agent. In some embodiments, the HBV RNAi agent comprises a sense and an anti-sense strand, each strand being an 18-mer and the strands together forming a blunt-ended duplex, wherein the 3? end of at least one strand terminates in a phosphate or modified internucleoside linker and further comprises, in 5? to 3? order: a spacer; a second phosphate or modified internucleoside linker; and a 3? end cap. In some embodiments, the 3? end of both the sense and anti-sense strand further comprise, in 5? to 3? order: a spacer; a second phosphate or modified internucleoside linker; and a 3? end cap. The two strands can have the same or different spacers, phosphates or modified internucleoside linkers, and/or 3? end caps. The strands can be ribonucleotides, or, optionally, one or more nucleotide can be modified or substituted. Optionally, at least one nucleotide comprises a modified internucleoside linker.

Abstract: The disclosure relates to novel compounds and compositions comprising a RNAi agent comprising a novel compound as a 3? end cap. The disclosure also relates to processes for making such compositions, and methods and uses of such compositions, e.g., to mediate RNA interference.

Abstract: A method of cutting a tubular includes providing a rotatable cutting tool in the tubular, the cutting tool having a blade with a cutting structure thereon; extending the blade relative to the cutting tool; rotating the cutting tool relative to the tubular; guiding the cutting structure into contact with the tubular; cutting the tubular using the blade; and limiting extension of the blade.

Abstract: A method of cutting a tubular includes providing a rotatable cutting tool in the tubular, the cutting tool having a blade with a cutting structure thereon; extending the blade relative to the cutting tool; rotating the cutting tool relative to the tubular; guiding the cutting structure into contact with the tubular; cutting the tubular using the blade; and limiting extension of the blade. A rotatable blade for cutting a tubular includes a blade body extendable from a retracted position; a cutting structure disposed on a leading edge of the blade body, the cutting structure configured to cut the tubular; a stop on a first surface of the blade body; and an initial engagement point on a second surface of the blade body, the initial engagement point configured to guide the cutting structure into contact with the tubular.

Abstract: The present disclosure relates to compositions and methods for treating APOC3-related diseases such as: hypertriglyceridemia (e.g., Type V Hypertriglyceridemia), abnormal lipid metabolism, abnormal cholesterol metabolism, atherosclerosis, hyperlipidemia, diabetes, including Type 2 diabetes, obesity, cardiovascular disease, and coronary artery disease, among other disorders relating to abnormal metabolism or otherwise, using a therapeutically effective amount of a RNAi agent to APOC3.

Abstract: In some examples, a technique may include positioning a first part comprising a ceramic or ceramic matrix composite and a second part comprising a ceramic or a CMC adjacent to each other to define a joint region at the interface of the first part and the second part. In some examples, the joint region may be heated using at least one of a laser or a plasma arc source to heat the joint region to an elevated temperature. The first and second parts may be pressed together and cooled to join the first and second parts at the joint region. In other examples, a solid braze material including a filler material and a metal or alloy may be delivered to the joint region and locally heated to cause a constituent of the filler material and a constituent of the metal or alloy to react. When reacted, the constituents may form a solid material, which may join the first and second parts.

Abstract: Telecommunications enclosures are described in this document. In one aspect, a telecommunications enclosure includes side panels having seals and an enclosure top connected, independent of a frame, to top ends of the side panels. The enclosure top has an enclosure top outer end that extends between the side panels and includes a seal. An interior panel is connected, independent of a frame, to side panels and has an interior panel outer end that extends between the side panels. The interior panel is separated from the enclosure top by a first distance and separated by a second distance from bottom ends of the side panels. A removable door is formed to engage the seals when the removable door is secured to the frameless telecommunications enclosure.

Abstract: Telecommunications enclosures are described in this document. In one aspect, a telecommunications enclosure includes side panels having seals and an enclosure top connected, independent of a frame, to top ends of the side panels. The enclosure top has an enclosure top outer end that extends between the side panels and includes a seal. An interior panel is connected, independent of a frame, to side panels and has an interior panel outer end that extends between the side panels. The interior panel is separated from the enclosure top by a first distance and separated by a second distance from bottom ends of the side panels. A removable door is formed to engage the seals when the removable door is secured to the frameless telecommunications enclosure.

Abstract: Exemplary embodiments of the present disclosure relate to systems, methods, and non-transitory computer-readable media for contemporaneous in-browser searching, viewing, tagging, and harvesting digital content in a networked environment, and for removing malignant content from the networked environment.

Abstract: This document discusses, among other things, a valve assembly for controlling an exhaust pressure of a gas combustion system. The valve assembly can include a valve housing, a flapper, and a biasing device. The valve housing can be coupleable to an exhaust pipe. The flapper can be pivotably couplable to the valve housing to pivot between a full open position and a restricted position in response to exhaust pressure. The biasing device can be couplable to the housing and extendable into the exhaust pipe to engage the flapper, where the biasing device can be configured to bias the flapper toward the restricted position and can be configured to resist movement of the flapper between the restricted position and the full open position.

Abstract: The present disclosure relates to compositions and methods for treating APOC3-related diseases such as: hypertriglyceridemia (e.g., Type V Hypertriglyceridemia), abnormal lipid metabolism, abnormal cholesterol metabolism, atherosclerosis, hyperlipidemia, diabetes, including Type 2 diabetes, obesity, cardiovascular disease, and coronary artery disease, among other disorders relating to abnormal metabolism or otherwise, using a therapeutically effective amount of a RNAi agent to APOC3.